Skip to main content
OpenTrials
Completed

NCT Number: NCT02906553

The Role of Nitric Oxide in Cognition in Schizophrenia

This study evaluates the role of the Nitric Oxide system in cognition in patients with schizophrenia. Participants will be randomised to 2 equal groups and receive either the Nitric Oxide donor molecule glyceryl trinitrate, or a placebo. Performance on several cognitive tasks will be assessed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

South London and Maudsley

London, SW9 9NT, United Kingdom

About this study

Nitric oxide [NO] is a gaseous neurotransmitter substance found in the brain. Nitric oxide is integrated with the glutamate system. Glutamate has received considerable attention as an important factor in the cognitive distortions and cognitive impairments that underlie schizophrenia. Deficits in glutamate in schizophrenia may impact upon cognition via the NO system, as glutamate receptors signal by way of NO.

Here the investigators aim to extend knowledge of glutamate-NO systems by directly examining the role of NO in cognition in patients with psychosis. We aim to assess the role of the NO system in cognition, downstream of glutamate and before patients are started on any anti-psychotic medication which perturb brain neurochemistry.

The primary outcome measure is change in a particular style of cognition referred to as 'jumping to conclusions' following the administration of a potent Nitric Oxide donor molecule [glyceryl trinitrate (GTN)], under placebo-controlled, double-blind conditions. This will shed light on the direct role of NO in cognition in psychosis, beyond the glutamate system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-40 years of age
  • Patients undergoing an acute psychotic episode (defined as score > 4 on question P1 of the PANSS positive subscale) requiring full-time hospitalisation according to clinical referral by the relevant mental health service
  • Demonstrates capacity and willing to give informed consent
  • Female participants willing to have a pregnancy test before treatment
  • Currently unmedicated with antipsychotic medication

Exclusion criteria

  • Major physical illness
  • Prior history of intolerance to glyceryl trinitrate
  • Homicidal or suicidal
  • Pregnant or breast feeding

Treatment and study plan

glyceryl trinitrate

Drug

Placebo

Drug

Primary outcomes

  1. The emotionally salient version of the Jumping to Conclusions (JTC) task

    Time frame: Change in performance from baseline to Day1, Day 2, Day 3, Day 7

Secondary outcomes

  1. The Hopkins Verbal Learning Task - Revised, immediate recall

    Time frame: Change from baseline to Day1, Day 2, Day 3, Day 7

  2. Positive and negative syndrome scale (PANSS) (videotaped)

    Time frame: Change from baseline to Day1, Day 2, Day 3, Day 7

  3. The Bond-Lader Visual Analog Scales

    Time frame: Change from baseline to Day1, Day 2, Day 3, Day 7

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • South London and Maudsley NHS Foundation Trust

Registry information

Official study title

The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study (Nitric Oxide in Cognition)

Acronym: NOC

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Sep 20, 2016
Registry last updated
Aug 13, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.